{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:13:07Z","timestamp":1770217987723,"version":"3.49.0"},"reference-count":1,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2001]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; The mechanism for ultraviolet-B (UVB)-associated cutaneous erythema may involve production of tumor necrosis factor \u03b1 (TNF-\u03b1). Pentoxifylline inhibits TNF-\u03b1 production. &lt;i&gt;Objective:&lt;\/i&gt; To assess the effect of oral pentoxifylline on UVB-induced erythema in humans. &lt;i&gt;Methods:&lt;\/i&gt; Baseline minimum erythema doses (MEDs) for UVB were measured. Subjects received pentoxifylline 400\u00a0mg orally every 8\u00a0h for 4 doses. MED assays were repeated 2\u00a0h after the last dose of pentoxifylline. Pre- and posttreatment MED results were assessed by the paired t test. &lt;i&gt;Results:&lt;\/i&gt; Oral administration of pentoxifylline to 7 normal adults elevated the MED for UVB in all 7 individuals. &lt;i&gt;Conclusion:&lt;\/i&gt; Pentoxifylline may diminish the cutaneous sunburn response to UVB radiation when it is administered prior to ultraviolet exposure.<\/jats:p>","DOI":"10.1159\/000051584","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T12:11:24Z","timestamp":1050408684000},"page":"44-45","source":"Crossref","is-referenced-by-count":5,"title":["Pentoxifylline Attenuates UVB-Induced Cutaneous Erythema"],"prefix":"10.1159","volume":"202","author":[{"given":"Mark H.","family":"Lowitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2001,3,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2744(199805)22:1<16::AID-MC3>3.0.CO;2-J"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/51584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/51584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:06:46Z","timestamp":1745467606000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000051584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000051584","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001]]}}}